FOURTH AMENDED AND RESTATED RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT BETWEEN THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH AND ATARA BIOTHERAPEUTICS, INC.Research and Development Collaboration Agreement • February 28th, 2022 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Fourth Amended and Restated Research and Development Collaboration Agreement (“Fourth Restated Agreement”), entered into on December 17, 2021 (“Execution Date”), and effective as of the Execution Date, is made by and between Atara Biotherapeutics, Inc., having its principal offices at 611 Gateway Blvd #900, South San Francisco, CA 94080, (“Atara”), and the Council of the Queensland Institute of Medical Research, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”). Each of Atara and Institute are referred to in this Agreement as a “Party”, and collectively as the “Parties”
ATARA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for [NAME]Employment Agreement • February 28th, 2022 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (this “Agreement”), is made and entered into as of [DATE] (the “Effective Date”), by and between [NAME] (“Employee”) and Atara Biotherapeutics, Inc. (the “Company”).
FOURTH AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT between THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH and ATARA BIOTHERAPEUTICS, INC.Exclusive License Agreement • February 28th, 2022 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This FOURTH AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (“Fourth Restated Agreement”) is entered into on December 17, 2021 (“Execution Date”), and effective as of the Execution Date, by and between the COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”), and ATARA BIOTHERAPEUTICS, INC., a Delaware corporation located at 611 Gateway Blvd #900, South San Francisco, CA 94080 (“Licensee”). Each of Licensee and Institute are referred to in this Agreement as a “Party” and together, the “Parties”.
COMMERCIALIZATION AGREEMENTCommercialization Agreement • February 28th, 2022 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Commercialization Agreement (this “Agreement”) is made as of October 2, 2021 (the “Effective Date”), by and between Atara Biotherapeutics, Inc., incorporated under the laws of Delaware and having its registered office at 611 Gateway Blvd., Suite 900, South San Francisco, CA 94080 (“Atara”), and Pierre Fabre Medicament, having its registered office at 45, place Abel Gance, 92100 Boulogne Billancourt, France (“Partner”). Atara and Partner are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO LEASELease • February 28th, 2022 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of December 9, 2021, by and between 611 GATEWAY CENTER LP, LLC, a Delaware limited partnership (“Landlord”), and ATARA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).
